Home > Products > CD19 & CD64 > Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc)

Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc)  (CAT#: BSCFV-044)

Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD19 specificity or anti-CD64 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget neutrophils to tumor cells. It is designed for the research of B cell lymphoma; Leukemia therapy.
Datasheet INQUIRY

Specifications

Targets
CD19 & CD64
Type
scFv-based Bispecific Fragments
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
B cell lymphoma; Leukemia

Targets

Target 1
CD19
Gene ID
UniProt ID
Alternative Names
CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Target 2
CD64
Gene ID
UniProt ID
Alternative Names
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD19 & CD64"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD19 x Anti-CD64 Bispecific Antibody (scFv-Fc) (BSCFV-044). Click the button below to contact us or submit your feedback about this product.